Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
about
Novel systemic therapy against malignant pleural mesothelioma.Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesotheliomaPrognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.Investigational approaches for mesothelioma.Malignant pleural mesothelioma: an update on diagnosis and treatment options.Optimization of response classification criteria for patients with malignant pleural mesothelioma.Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesotheliomaChemotherapy for malignant pleural mesothelioma: a review of current management and a look to the futureSystemic treatments for mesothelioma: standard and novel.Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.Future developments in the management of malignant pleural mesothelioma.Malignant pleural mesothelioma: current treatments and emerging drugs.Medical treatment of mesothelioma: anything new?Systemic treatment of malignant pleural mesothelioma.miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma.microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53Multimodality treatment of malignant pleural mesothelioma
P2860
Q33890499-05DDD43C-0C16-4435-B7E7-6F644AA4ACA0Q33914000-4963F802-395F-462C-99B6-5E1CC02BC207Q33918135-C59A01BB-A801-4E7B-8430-98E39C5D06F4Q34293068-1B7A01F7-F7F9-4001-9FDC-9E027AD40E64Q34513958-9853246E-67D7-47E3-85A4-A8EB65DC2170Q36322856-719931DB-0838-45F4-A251-80F3670F352EQ36821171-AF5BFA5B-9A4C-45C4-8124-5D3302D7AF42Q37090808-829F571B-F31F-4A66-9C7F-1F74E730EB46Q37260408-BF159BEF-2D86-4349-B167-AEBED22A6680Q37290519-53602C92-476E-4C17-AB71-E3DC8D305C76Q37449036-DA0E3FA4-2D3C-4C21-AFDB-D68DCC55821CQ37529848-B1D1FBA9-1371-4497-A8C3-9500F84C5FFFQ37866663-70C14D74-DA1D-4C11-92DE-5E150BB78569Q37992694-ACEC1C67-57BD-413C-B60F-8B0A2B872E49Q40466065-EE7062B7-61EF-4945-88B2-D1471E1AE7BEQ41847770-1B158EEE-0403-4083-A83F-739E01AAE65FQ42412951-15E2C654-FA02-4D70-93D1-6FA304FC0BECQ45020726-22BC5BDC-905E-4EC5-A7FF-9F2F693099AEQ52672893-41770BEA-5F18-42D1-B155-1790269368F7Q55346721-000B27CA-8494-4FC6-8461-E017C388ACE6Q56976088-E6AF106D-7447-4326-BC46-9079D6E5F6A4Q58580151-2F78815F-BFAA-4D54-BC6F-D06AB93F65B8
P2860
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Pemetrexed plus carboplatin in ...... alysis of two phase II trials.
@ast
Pemetrexed plus carboplatin in ...... alysis of two phase II trials.
@en
type
label
Pemetrexed plus carboplatin in ...... alysis of two phase II trials.
@ast
Pemetrexed plus carboplatin in ...... alysis of two phase II trials.
@en
prefLabel
Pemetrexed plus carboplatin in ...... alysis of two phase II trials.
@ast
Pemetrexed plus carboplatin in ...... alysis of two phase II trials.
@en
P2093
P2860
P50
P356
P1476
Pemetrexed plus carboplatin in ...... nalysis of two phase II trials
@en
P2093
A Ceribelli
B Castagneto
D Cortinovis
F De Vincenzo
G Del Conte
G L Ceresoli
M Marangolo
M Mencoboni
P A Zucali
P2860
P2888
P356
10.1038/SJ.BJC.6604442
P407
P577
2008-06-10T00:00:00Z
P5875
P6179
1006397256